Stock AnalizMineralys Therapeutics, Inc. MLYS
Biotechnology: Pharmaceutical Preparations · IPO 2023 · data as of November 13, 2026
Mineralys Therapeutics, Inc. (MLYS) is a healthcare company listed in the US with a market value of about $1.4B.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -43%.
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 4 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Net income | -$155M | -$178M | -$72M | -$30M |
| Free cash flow | -$142M | -$166M | -$81M | — |
| EPS (diluted) | $-2.29 | $-3.66 | $-1.99 | $-5.77 |
| Net margin | — | — | — | — |
| ROIC | -20.8% | -79.5% | -27.7% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $43.56, 184% above the current price; targets range from $19.00 to $56.00; the consensus rating is “Strong buy”; expected EPS is $-4.59 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Mineralys Therapeutics pay a dividend?
Not currently.
Is Mineralys Therapeutics a good stock to buy?
We do not give buy or sell advice. Mineralys Therapeutics scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.